Trinity Biotech has entered a strategic collaboration with Latch Medical to combine its AI-native CGM+ wearable biosensor platform with Latch Medical's Pharma Latch intradermal drug delivery technology, aiming to develop precision therapeutic solutions for diabetes, obesity and other metabolic conditions. The companies will explore how real-time metabolic data from CGM+ can guide and optimise therapeutic delivery, potentially enabling more personalised and responsive treatments. As part of the deal, Trinity Biotech has agreed in principle to make a strategic equity investment in Latch Medical, which has previously attracted investment from established participants in the global drug delivery industry. Trinity Biotech's largest financial investor, Perceptive Advisors, is supporting the investment. The collaboration expands CGM+ beyond monitoring and supports Trinity Biotech's strategy of building an integrated metabolic health platform combining continuous sensing, AI-driven insights and precision therapeutic delivery.
Trinity Biotech plcLatch Medical enters a strategic collaboration with Trinity Biotech to combine its drug delivery tech with CGM+, and receives a strategic equity investment.